Product Description: Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.
CAS Number: 1449294-76-1
Molecular Weight: N/A
Compound Purity: 96.44
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Toll-like Receptor (TLR)